During the 2HFY2021, Cordlife’s revenue grew 3.3% y-o-y to $29.4 million as contributions from its banking and diagnostics segments increased.
Soochow CSSD Capital Markets analyst Simeon Ang is maintaining his “buy” recommendation on Cordlife Group with an unchanged target price of 47 cents after the group’s FY2021 results surpassed Ang’s lowered expectations.
For the FY2021 ended December, the group’s revenue and NPAT stood at 103% and 132% of Ang’s trimmed expectations on the back of a h-o-h growth in its overall performance.
